Nab-paclitaxel-based regimens with docetaxel-based regimens as neoadjuvant treatment for early breast cancer
Conclusions This study presented antitumor activity of nPBC and DBC in patients with early breast cancer receiving neoadjuvant treatment in a real-world setting. Further prospective research is warranted to confirm the results and to develop biomarkers for better patient selection.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Abraxane | Brain | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Docetaxel | Drugs & Pharmacology | Hematology | Investigational New Drugs | Nanotechnology | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Neurology | Neurosurgery | Study | Taxotere | Toxicology